Grand Pharmaceutical Group Limited (0512.HK)
HKD 5.91
(0.34%)
HKD 5.91
(0.34%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 1.87 Billion HKD | -9.59% |
| 2022 | 2.07 Billion HKD | -13.45% |
| 2021 | 2.4 Billion HKD | 34.02% |
| 2020 | 1.79 Billion HKD | 55.76% |
| 2019 | 1.15 Billion HKD | 61.5% |
| 2018 | 712.66 Million HKD | 54.65% |
| 2017 | 460.81 Million HKD | 71.21% |
| 2016 | 269.14 Million HKD | 48.78% |
| 2015 | 180.9 Million HKD | 3.25% |
| 2014 | 175.2 Million HKD | 75.81% |
| 2013 | 99.65 Million HKD | 48.07% |
| 2012 | 67.3 Million HKD | 24.1% |
| 2011 | 54.23 Million HKD | -44.64% |
| 2010 | 97.97 Million HKD | 245.66% |
| 2009 | 28.34 Million HKD | 216.96% |
| 2008 | -24.23 Million HKD | 53.42% |
| 2007 | -52.03 Million HKD | -335.73% |
| 2006 | -11.94 Million HKD | 89.03% |
| 2005 | -108.8 Million HKD | 30.48% |
| 2004 | -156.5 Million HKD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 1.55 Billion HKD | 0.0% |
| 2023 FY | 1.87 Billion HKD | -9.59% |
| 2023 Q2 | 1.02 Billion HKD | 0.0% |
| 2023 Q4 | 850.64 Million HKD | 0.0% |
| 2022 FY | 2.07 Billion HKD | -13.45% |
| 2022 Q2 | 710.41 Million HKD | 0.0% |
| 2022 Q4 | 1.36 Billion HKD | 0.0% |
| 2021 Q4 | 1.2 Billion HKD | 0.0% |
| 2021 FY | 2.4 Billion HKD | 34.02% |
| 2021 Q2 | 1.2 Billion HKD | 0.0% |
| 2020 Q4 | 1.07 Billion HKD | 0.0% |
| 2020 Q2 | 718.5 Million HKD | 0.0% |
| 2020 FY | 1.79 Billion HKD | 55.76% |
| 2019 Q4 | 603.99 Million HKD | 0.0% |
| 2019 FY | 1.15 Billion HKD | 61.5% |
| 2019 Q2 | 546.95 Million HKD | 0.0% |
| 2018 FY | 712.66 Million HKD | 54.65% |
| 2018 Q2 | 315.43 Million HKD | 0.0% |
| 2018 Q4 | 397.23 Million HKD | 0.0% |
| 2017 FY | 460.81 Million HKD | 71.21% |
| 2017 Q2 | 205.9 Million HKD | 0.0% |
| 2017 Q4 | 254.9 Million HKD | 0.0% |
| 2016 Q4 | 158.31 Million HKD | 0.0% |
| 2016 Q2 | 110.83 Million HKD | 0.0% |
| 2016 FY | 269.14 Million HKD | 48.78% |
| 2015 Q4 | 101.77 Million HKD | 0.0% |
| 2015 Q2 | 79.13 Million HKD | 0.0% |
| 2015 FY | 180.9 Million HKD | 3.25% |
| 2014 Q4 | 114.83 Million HKD | 0.0% |
| 2014 Q2 | 60.37 Million HKD | 0.0% |
| 2014 FY | 175.2 Million HKD | 75.81% |
| 2013 Q4 | 65.37 Million HKD | 0.0% |
| 2013 FY | 99.65 Million HKD | 48.07% |
| 2013 Q2 | 34.28 Million HKD | 0.0% |
| 2012 Q2 | 26.17 Million HKD | 0.0% |
| 2012 FY | 67.3 Million HKD | 24.1% |
| 2012 Q4 | 26.32 Million HKD | 0.55% |
| 2012 Q3 | 26.17 Million HKD | 0.0% |
| 2012 Q1 | 26.17 Million HKD | 0.0% |
| 2011 Q2 | 21.66 Million HKD | 0.0% |
| 2011 Q3 | 21.66 Million HKD | 0.0% |
| 2011 Q4 | 26.17 Million HKD | 20.81% |
| 2011 FY | 54.23 Million HKD | -44.64% |
| 2011 Q1 | 21.66 Million HKD | 0.0% |
| 2010 Q1 | 38.56 Million HKD | 0.0% |
| 2010 Q3 | 38.56 Million HKD | 0.0% |
| 2010 Q4 | 21.66 Million HKD | -43.82% |
| 2010 FY | 97.97 Million HKD | 245.66% |
| 2010 Q2 | 38.56 Million HKD | 0.0% |
| 2009 Q1 | 10.47 Million HKD | 0.0% |
| 2009 Q3 | 10.47 Million HKD | 0.0% |
| 2009 Q4 | 38.56 Million HKD | 268.09% |
| 2009 FY | 28.34 Million HKD | 216.96% |
| 2009 Q2 | 10.47 Million HKD | 0.0% |
| 2008 Q2 | -5.67 Million HKD | 0.0% |
| 2008 Q4 | 10.47 Million HKD | 284.78% |
| 2008 Q1 | -5.67 Million HKD | 0.0% |
| 2008 FY | -24.23 Million HKD | 53.42% |
| 2008 Q3 | -5.67 Million HKD | 0.0% |
| 2007 Q1 | -13.47 Million HKD | 0.0% |
| 2007 Q4 | -5.67 Million HKD | 57.9% |
| 2007 Q3 | -13.47 Million HKD | 0.0% |
| 2007 Q2 | -13.47 Million HKD | 0.0% |
| 2007 FY | -52.03 Million HKD | -335.73% |
| 2006 Q4 | -13.47 Million HKD | -351.26% |
| 2006 FY | -11.94 Million HKD | 89.03% |
| 2006 Q2 | -2.98 Million HKD | 0.0% |
| 2006 Q3 | -2.98 Million HKD | 0.0% |
| 2006 Q1 | -2.98 Million HKD | 0.0% |
| 2005 Q2 | -27.2 Million HKD | 0.0% |
| 2005 Q4 | -2.98 Million HKD | 89.03% |
| 2005 FY | -108.8 Million HKD | 30.48% |
| 2005 Q1 | -27.2 Million HKD | 0.0% |
| 2005 Q3 | -27.2 Million HKD | 0.0% |
| 2004 Q2 | -39.12 Million HKD | 0.0% |
| 2004 Q3 | -39.12 Million HKD | 0.0% |
| 2004 Q1 | -39.12 Million HKD | 0.0% |
| 2004 Q4 | -27.2 Million HKD | 30.48% |
| 2004 FY | -156.5 Million HKD | 0.0% |
| 2003 Q4 | -39.12 Million HKD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 105.03 Million HKD | -1689.809% |
| Extrawell Pharmaceutical Holdings Limited | -162.94 Million HKD | 1253.734% |
| Wai Yuen Tong Medicine Holdings Limited | -15.35 Million HKD | 12342.759% |
| Qianhai Health Holdings Limited | -52.7 Million HKD | 3667.02% |
| Lee's Pharmaceutical Holdings Limited | 16.69 Million HKD | -11158.821% |
| Essex Bio-Technology Limited | 275.25 Million HKD | -582.991% |
| Tongfang Kontafarma Holdings Limited | -28.84 Million HKD | 6618.039% |
| PuraPharm Corporation Limited | -106.08 Million HKD | 1872.229% |
| SSY Group Limited | 1.31 Billion HKD | -42.574% |
| JBM (Healthcare) Limited | 130.46 Million HKD | -1341.02% |
| Jacobson Pharma Corporation Limited | 266.96 Million HKD | -604.204% |
| China Resources Pharmaceutical Group Limited | 3.85 Billion HKD | 51.223% |